Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics (Nasdaq: CGEM) has announced its participation in two major upcoming investor conferences in March 2025.
Rhea-AI Summary
Cullinan Therapeutics (Nasdaq: CGEM) has announced its participation in two major upcoming investor conferences in March 2025. The company's leadership team, including Chief Executive Officer Nadim Ahmed and Chief Medical Officer Jeffrey Jones, will engage in fireside chats at both events.
The first appearance will be at the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025, at 11:10 a.m. ET. The second presentation is scheduled for the Leerink Partners Global Healthcare Conference in Miami Beach on March 11, 2025, at 11:20 a.m. ET.
Investors and interested parties can access webcasts of both fireside chats through the Events and Presentations section of Cullinan's investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CGEM
The recorded move for CGEM in the trading session of this news was -3.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Tuesday, March 4, 2025, at 11:10 a.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025, at 11:20 a.m. ET.
Webcasts of the fireside chats will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.